Home Compare ALNY vs ARGX.BR
Stock Comparison · Industry comparison · Biotechnology

Alnylam Pharmaceuticals vs argenx: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Alnylam Pharmaceuticals carrying a narrow edge on growth. argenx SE still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the lead runs through growth, while profitability helps make the separation broader.

INDUSTRY COMPARISON

Both operate in: Biotechnology

This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and ARGX.BR share the same industry classification.

For a similarity-based comparison, see how Alnylam Pharmaceuticals and argenx SE each position within their functional peer groups in AssetNext.

Peer-Relative Score
ALNY
Alnylam Pharmaceuticals, Inc.
56
Peer-Score
Signal qualityHigh
vs
ARGX.BR
argenx SE
51
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: ALNY vs ARGX.BR Profitability 78 53 Stability 53 77 Valuation 14 37 Growth 91 42 ALNY ARGX.BR
Gap Ranking
#1 Growth +49
#2 Profitability +25
#3 Stability +24
#4 Valuation +23
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ALNY and ARGX.BR Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ALNYARGX.BR Relative valuation Structural strength

Alnylam Pharmaceuticals, Inc. still looks stronger overall, though current pricing looks more supportive for argenx SE.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both rank well on growth, but Alnylam Pharmaceuticals, Inc. still holds a clear edge.
Profitability
On profitability, the same pattern holds: both rank well, but Alnylam Pharmaceuticals, Inc. still sits higher.
Growth — Dominant Gap
ALNY
91
ARGX.BR
42
Gap+49in favour of ALNY

The main growth separation is very wide, driven by a meaningfully stronger expansion profile.

What keeps the gap from being one-sided

A meaningful counterforce remains in stability, which keeps the comparison from looking completely one-sided.

What this means for the comparison

The lead is built on both growth and profitability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the ALNY vs ARGX.BR comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how ALNY and ARGX.BR each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.